We asked whether the plasma levels of MCP-1/CCL-2, which is a signature inflammatory marker, were elevated in T2D patients with asthma as compared with those having either diabetes or asthma or none of the morbid condition. This evidence concerns the gene CCL2 and type 2 diabetes mellitus.